Loading
New York oncologist who led KEYNOTE-775, the trial that established lenvatinib plus pembrolizumab for advanced endometrial cancer after chemotherapy.
Vicky Makker is a gynaecologic medical oncologist at Memorial Sloan Kettering Cancer Center. She led the phase 2 study and was first author of the 2022 New England Journal of Medicine report of KEYNOTE-775, the phase 3 trial in which lenvatinib plus pembrolizumab improved progression-free and overall survival compared with chemotherapy in advanced endometrial cancer after platinum-based therapy, including mismatch repair-proficient tumours.
| Title | Journal | Year |
|---|---|---|
| KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer | New England Journal of Medicine | 2022 |
Shares Advanced or recurrent endometrial cancer, Endometrial cancer and the tags endometrial, gynaecological, trialist.
Shares Endometrial cancer and the tags endometrial, gynaecological, immunotherapy, trialist.
Shares Endometrial cancer and the tags endometrial, gynaecological, trialist.
Shares Endometrial cancer and the tags endometrial, immunotherapy.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares KEYNOTE-775: lenvatinib plus pembrolizumab versus chemotherapy for previously treated advanced endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Endometrial cancer and the tags endometrial, trialist.
Shares Endometrial cancer and the tags endometrial, trialist.